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LIST OF ABBREVIATIONS
ROCK: Rho-Kinase 
SASP: Senescence-associated secretory phenotype 
IL: Interleukin 
p38 MPAK: p38 mitogen-activated protein kinase
IL-1RA: Interleukin 1 receptor antagonist
mTOR: Mammalian target of rapamycin 
ELISA: Enzyme-linked immunosorbent assay
NOK: Normal oral keratinocyte
OD: Oral dysplasia
SA--Gal: Senescence-associated beta-galactosidase
EMT: Epithelial-to-mesenchymal transition 
IL-1R1: Interleukin 1 receptor 1
IRAK1: Interleukin 1 receptor associate kinase 1 
NF-B: nuclear factor kappa-light-chain-enhancer of activated B cells
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ABSTRACT
Senescent cells accumulate in different organs and develop a senescence-associated secretory 
phenotype (SASP), associated with the development of age-related pathologies. The constitution 
of the SASP varies among cell types and with the method of senescence induction; nevertheless, 
there is substantial overlap among SASPs, especially the presence of pro-inflammatory cytokines 
such as IL-1, IL-1, IL-6 and IL-8. These cytokines are highly conserved among SASPs and are 
implicated in the development of several cancers. Here, we report that ROCK inhibition by Y-
27632 reduces levels of IL-1, IL-1, IL-6 and IL-8 secreted by senescent normal and dysplastic 
oral keratinocytes without affecting the permanent cell growth arrest. The data indicate some 
inflammatory genes downregulated by Y-27632 remain downregulated even after repeated 
passage in the absence of Y-27632. We propose ROCK kinase inhibition as a novel alternative to 
current strategies to modulate the inflammatory components of the SASP, without compromising 
the permanent cell growth arrest. This observation potentially has wide clinical applications, given 
the involvement of senescence in cancer and a wide range of age-related disease. It also 
suggests care should be exercised when using Y-27632 to facilitate cell expansion of primary 
cells, as its effects on gene expression are not entirely reversible.
INTRODUCTION
Senescence is a cellular state characterized by permanent cell growth arrest in response 
to different stressors [1]. It is considered a potent tumour-suppressor mechanism [2-4], because it 
can stop cells with somatic mutations (considered as pre-cancerous cells) from dividing and 
acquiring further mutations that could enable replicative immortality and cancer development [5]. 
Despite this, senescence is associated with the development of age-related diseases, including 
cancer [6, 7]. Senescent cells have a characteristic gene expression profile [8] and secrete more 
than 40 pro-inflammatory molecules (cytokines, chemokines, growth factors and proteases) 
involved in intercellular signalling; a phenotype recognized as the senescence-associated 
secretory phenotype (SASP) [7, 9]. The transcriptome and secretome of the SASP varies among 
cell types and with aetiology of senescence (telomere shortening, oncogene activation, etc.) [10, 
11], which reflects the heterogeneity of the SASP. Nevertheless, there is substantial overlap 
among SASPs, especially with pro-inflammatory cytokines such as IL-1, IL-1, IL-6 and IL-8, 
which are highly conserved among SASPs [12].
In the context of tumorigenesis, senescence can be a beneficial response, preventing 
cells with oncogenic mutations dividing, thus preventing cancer. But the development and 
dysregulation of the SASP can have the opposite effects. Thus, different approaches, using a A
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variety of agents to target the SASP or key SASP factors have been employed, which includes 
the use of: metformin [13], C75 (a fatty acid synthase inhibitor) [14], p38MAPK inhibitors [15], 
rapamycin (mTOR inhibitor) [16] and anakinra (exogenous IL-1RA) [17]. 
Rho kinase (ROCK) is a downstream target of the small GTP-binding protein Rho, and 
has two isoforms, ROCK1 and ROCK2 [18, 19]. ROCKs belong to the serine threonine kinase 
family which modulate various important cellular functions, such as cell shape, motility, secretion, 
cellular growth, apoptosis, gene expression and cell cycle progression [20]. Because of that, 
ROCK inhibitors have been proposed as novel therapeutics in a number of clinical scenarios, 
including; asthma [21], glaucoma [22], systemic lupus erythematosus [23], cardiovascular 
diseases [24, 25], bone healing [26], and cancer [27], among others. 
IL-1 signalling is essential for the development of the SASP and its oncogenic properties 
[28]. Both IL-1 and IL-1 are able to increase secretion of SASP factors such as IL-6 and IL-8, 
which have known oncogenic properties [7, 28, 29] and IL-1 inactivation in senescent cells 
impairs tumour progression [28]. Recently, the ROCK inhibitor Y-27632 was shown to reduce IL-
1-induced IL-8 secretion in Caco-2 cells, by reducing the phosphorylation of p38 MAPK [30]. 
Similar to this, another study reported Y-27632  reduced LPS-induced IL-6 and IL-8 secretion in 
human gingival fibroblasts, by inactivating the NF-B and p38 MAPK pathways. Due to its ability 
to inhibit IL-1 signalling and the importance of the IL-1 pathway for the development of the SASP, 
we investigated the effects of Y-27632 on pre-senescent and senescent cells and examined if Y-
27632 could modulate the expression of commonly expressed SASP factors related with cancer 
development. Y-27632 is commonly used in cell biology to facilitate the manipulation of primary 
cell cultures, as treated cells are able to proliferate indefinitly without genetic alterations [31]. 
Nevertheless, it is not known how reversible its effects are and what other consequences may be 
in the cells. Thus, we also explored the reversibility of Y-27632 effects.
RESULTS
Y-27632 modifies the SASP from senescent normal and dysplastic oral keratinocytes
To analyze the effects of ROCK inhibition on senescent cells, we treated normal 
(NOK805) and dysplastic (D6) senescent oral keratinocytes with a commonly used Rho-kinase 
inhibitor, Y-27632 [32]. First, we wanted to assess if Y-27632 was able to rescue senescent 
keratinocytes from permanent cell growth arrest (Fig.1A-D). In both senescent NOK805 and D6 
cell cultures, a decrease in SA--Gal staining was noted, but no differences in SA--Gal positive A
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cells (p > 0.05) nor consistent changes in p16 expression between Y-27632 treated and non-
treated cells were observed (Fig.1E). In both Y-27632 treated and non-treated cells (for both 
NOK805 and D6 cells), there were no increases in population doublings after exposure to Y-
27632 or nothing for 6 days, confirming that in neither cell type Y-27632 was able recapitulate cell 
proliferation (Fig.1F). 
To study the effects of Y-27632 on the SASP, senescent NOK805 and D6 cells were 
treated for a period of 24 hours or 6 days with Y-27632 (10 g/ml). Conditioned media (CM) was 
collected and secreted levels of commonly expressed SASP factors (IL-6, IL-8, IL-1 and IL-1,) 
[12] were analyzed using ELISA. In senescent normal oral keratinocytes, Y-27632 reduced IL-6, 
IL-8, and IL-1 levels significantly at both time intervals (p < 0.05), apart from IL-1 levels which 
were decreased only after 24 hours treatment (Fig.2.A-D). In senescent dysplastic oral 
keratinocytes, there was a significant decrease in IL-6 and IL-8 levels after 24 hours and 6 days 
treatment with Y-27632 (p < 0.05). IL-1 levels also decreased but only after 6 days treatment (p 
< 0.05), and no significant changes in IL-1 levels were observed (Fig.2.E-H).
Changes in gene expression induced by Y-27632 are not always reversible 
Next, we assessed if changes in SASP cytokine expression induced by Y-27632 are 
reversible upon Y-27632 removal from culture conditions. For this purpose, we used primary 
normal oral keratinocytes (NOK805). NOK805 cells were passaged once without Y-27632, three 
times with 10 g/ml of Y-27632, and then two more times without Y-27632. Control cells 
(NOK805 cells without exposure to Y-27632) were passaged the same number of times. Primary 
keratinocytes have a limited lifespan in culture, usually senescing between 8-12 passages. 
Because of that, SA--Gal activity was quantified at start and endpoint. Y-27632 significantly 
reduced IL-1 and IL-8 mRNA transcripts, which remained significantly lower even two passages 
after the drug was removed (Fig.3.A-B). No significant changes in IL-1 and IL-6 mRNA 
transcripts were observed during or after treatment with Y-27632 (Fig.3.C-D).
Chemically immortalized keratinocytes senesce after Y-27632 removal from culture 
conditions
When studying the effects of Y-27632 on gene expression, we made the observation that 
SA--Gal activity remained very low or undetectable when the cells were grown under Y-27632 A
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treatment. Once Y-27632 was removed from culture conditions, a progressive increase in SA--
Gal activity was observed, suggesting a reactivation of the senescence program. Although one 
study reported cell growth arrest after Y-27632 removal [33], it was not demonstrated that the 
growth arrest reported was senescence. Thus, we assessed the capabilities of cells grown in the 
presence of Y-27632 to senesce after drug removal. Normally, NOK805 and D6 cells senesce at 
passage 10 and 8 respectively. We added 10 g/ml of Y-27632 to the growth media of NOK805 
and D6 at passage 2 and 3 respectively and cultured them to passage 18 and 17 (cells were still 
proliferative at this point) with no evidence of SA--Gal activity (Fig.4). We removed Y-27632 from 
culture conditions at passage 12 (NOK805) and 11 (D6) and observed cessation of cell growth 
after 1 passage in NOK805 and 2 passages in D6. The cell growth arrest corresponded with high 
SA--Gal activity (> 90%) and p16 expression in both cell cultures (Fig.4).   
DISCUSSION
During aging, senescent cells accumulate in different organs and develop a secretory 
phenotype, known as the SASP, which has been related with the development of age-related 
pathologies [34]. During early stages, components of the SASP facilitate tissue repair, immune 
surveillance and remodelling [35], but in advanced stages, the persistence of the SASP 
negatively impacts the microenvironment by enabling a chronic inflammatory state dominated by 
IL-1, IL-6 and IL-8 [28] through cell and non-cell autonomous effects [36]. It has been 
experimentally demonstrated that some senescent cells, such as fibroblasts, can promote 
carcinogenesis of keratinocytes via factors present in the SASP [6, 37]. Coppe et al., (2008) 
showed that the SASP from surrounding fibroblasts can induce EMT and invasion of pre-
malignant breast epithelial cells by a paracrine mechanism dependent on IL-6 and IL-8 [7]. 
Similar results have been shown elsewhere [38]. The SASP also favours the emergence, 
maintenance and migration of cancer stem cells [39]. All of these reports provide evidence of the 
pro-tumorigenic actions attributed to the SASP through IL-6 and IL-8. Thus, the modulation of 
SASP factors has promising clinical implications for the treatment of premalignancies and cancer.
Various attempts have been made to reduce the deleterious effects of senescent cells, 
whether by selective elimination of cells or by controlling the expression of specific SASP factors. 
Here, we report the ROCK inhibitor Y-27632 decreases release of IL-6 and IL-8 SASP by A
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senescent epithelial cells, which is likely to be a consequence of IL-1 inhibition. Both IL-1α and IL-
1 are crucial for the development of the SASP, and are regulators of IL-6 and IL-8 secretion 
through NF-B activation [28, 40, 41]. IL-1α regulates the SASP via IL-1R1, as depleting cells of 
IRAK1 (a downstream kinase recruited after IL-1R1 activation) reduces IL-6 levels even after IL-1 
stimulation [42]. IL-1α depletion also reduces NF-kB activity, which is important for IL-6 and IL-8 
secretion [42]. We observed Y-27632 reduces IL-1α levels in both normal and dysplastic cell 
cultures. A significant decrease in IL-1 levels was also observed but only in normal oral 
keratinocytes, as in dysplastic oral keratinocytes the decrease did not reach statistical 
significance. This is probably because IL-1 levels were almost undetectable in senescent 
dysplastic cells (between 0.005 and 0.07 pg/10.000 cells). Importantly, we also showed that 
senescent cells treated with Y-27632 do not restart proliferation, which is important if we want to 
modify the SASP without compromising the permanent cell growth arrest (desirable in the context 
of cancer, but also in other age-associated pathologies)[43].
Y-27632 is commonly used in cell culture as a facilitator of cell growth of primary 
keratinocytes due to its ability to enhance proliferation and to prolong cell lifespan. This is 
achieved by downregulation of keratinization and epithelial cell differentiation genes, and by 
upregulation of DNA replication, RNA processing, cell cycle and division genes [33]. It has been 
previously reported that Y-27632 can affect IL-1 signalling in proliferating cells [30, 44], but 
whether its effects are reversible upon drug withdrawal has not been assessed. This is of 
importance as when Y-27632 treated cells are used for experimentation, Y-27632 is usually 
removed from cell culture conditions 24 hours prior experimentation, with the assumption that the 
effects of the drug wear off after that time. We demonstrate that gene expression affected by Y-
27632 does not recover immediately after Y-27632 withdrawal. In our study, IL-1 and IL-8 RNA 
transcript levels did not recover even after passaging the cells twice after Y-27632 was removed 
(at least 10 days in culture). This has to be taken into consideration when using cells previously 
cultured with Y-27632 for downstream experiments, as transcription of some genes might not 
recover to pre-treatment levels, with likely phenotypic consequences.
Addition of Y-27632 to the growth media in combination with a 3T3 fibroblast feeder layer 
has been shown to indefinitely prolong keratinocyte lifespan [31, 45], but the indefinite lifespan is 
conditional on the presence of both [31]. Nevertheless, it is unknown if keratinocytes previously 
treated with Y-27632 are able to senesce once the drug has been removed. There is only one 
report showing that after Y-27632 removal keratinocytes stopped proliferating, but it is unclear if 
the growth arrest was due to terminal differentiation, quiescence or senescence, as no 
senescence markers were assessed [33]. This is of importance as it would render Y-27632 A
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suitable for use in experiments aiming to elucidate mechanisms of senescence in primary cells. 
To date, there is no single universal marker that can identify senescent cells from non-
proliferating, terminally differentiated or quiescent cells. Instead, a combination of multiple 
markers is used to identify senescent cells. We assessed senescence by evaluating SA--Gal 
activity and p16 expression, two commonly used markers to identify senescent cells [46]. We 
showed that keratinocytes previously treated with Y-27632 enter a non-proliferative phase shortly 
after Y-27632 has been removed from culture conditions, with high SA--Gal activity and high 
p16 expression, consistent with a senescence growth arrest. 
To summarize, we showed that ROCK kinase inhibition reduces the abundance of IL-1, 
IL-1, IL-6 and IL-8 released by senescent cells, without compromising the permanent cell growth 
arrest. Our data therefore suggests that Y-27632 is able to suppress the SASP, which could have 
wide clinical applications in cancer and other age-associated diseases. Finally, our results 
demonstrate care has to be taken when using Y-27632 to facilitate cell expansion of primary 
cells, as its effects on gene expression are not entirely reversible.  
METHODS
Cell culture:
Isolation of primary normal oral keratinocytes (NOK805) was done under The University of 
Sheffield ethics (approval reference 3463). The experiments were undertaken with the 
understanding and written consent of each subject. The study methodologies conformed to the 
standards set by the Declaration of Helsinki. 
The mortal dysplastic oral keratinocytes (D6) used in this study has been described previously 
[47]. Both D6 and NOK805 cells were grown using lethally irradiated (i) 3T3 feeders as described 
previously [48] in Dulbecco’s Modified Eagle Medium low glucose (DMEM) (Sigma-Aldrich, 
Gillingham, UK) containing 10% vol/vol foetal bovine serum (Hyclone FetalClone II 
Serum ,Fischer Scientific, New Hampshire, US)  and 21% vol/vol F12 nutrient mix (Sigma-Aldrich, 
Gillingham, UK), supplemented with 2 mM L-glutamine (Sigma-Aldrich, Gillingham, UK), 0.25 
g/ml adenine, 100 μg/ml penicillin and 100 U/ml streptomycin (Sigma-Aldrich, Gillingham, 
UK),10 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich, Gillingham, UK), 1 mg/ml human 
insulin (Sigma-Aldrich, Gillingham, UK), 4 g/ml hydrocortisone, 1.36 ng/ml and 5 g/ml 3, 3, 5-
Tri-iodothyronine/ Apo-Transferrin and 0.7 mM Na Pyruvate (Sigma-Aldrich, Gillingham, UK). All 
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cell cultures were incubated at 37ºC with 5% CO2 and checked daily. Medium was replaced 
every 2-3 days and cells were passaged when approximately 80% of confluency was achieved. 
Senescence associated  galactosidase staining
Twenty thousand cells per well were seeded in a 12 well-plate and left to adhere 
overnight. Senescence associated -Galactosidase activity was assessed using a senescence 
detection kit (ab65351, Abcam, Cambridge, UK) following the manufacturer’s recommendations.  
Treatment of proliferative oral keratinocytes with Y-27632
Y-27632 (Abcam, Cambridge, UK) was added to the growth media at a concentration of 10 g/ml 
and replaced every 2-3 days as described previously [49].
Treatment of senescent cells with Y-27632
NOK805 and D6 cells were grown until replicative senescence was achieved (confirmed by 
cessation of cell growth, morphological changes and a SA--Gal staining > 95% for each cell 
type). After confirmation, both NOK805 and D6 cells were treated for a period of 24 hours or 6 
days with 10 g/ml of Y-27632 (Abcam, Cambridge, UK) and conditioned media was collected.
Enzyme-linked immunosorbent assay (ELISA)
Secreted IL-6, IL-8, IL-1 and IL-1 were quantified using Elisa DuoSets from R&D 
Systems (Minneapolis, USA) for human IL-6, IL-8, IL-1 and IL-1 detection. The procedure was 
performed following the manufacturer’s recommendation using 96-well plates. Absorbance was 
read at 450 nm within 30 minutes of adding the stop solution. Wavelength correction was done 
subtracting absorbance at 570 nm from absorbance at 450 nm. 
Quantitative (q) PCR
Total RNA was extracted from cell pellets using the Isolate II RNA Mini Kit (Bioline) RNA 
extraction Kit following manufacturer’s instructions. RNA was quantified using a Nanodrop 1000 
Spectrophotometer (Thermo Fischer Scientific, Cambridge, UK). Five hundred nanograms of 
isolated RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
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(Applied Biosystems) following manufacturer´s protocol using a Peltier Thermal cycler (MJ 
Research). cDNA was then stored at -20ºC. 
Gene expression was quantified with a Rotor-gene Q real-time PCR cycler (Qiagen, 
Manchester, UK) using TaqMan chemistry. Quantification was calculated using delta CT values 
normalized to B2M. Each reaction was performed in triplicate. All reactions were performed in 
total volumes of 10 l loading 500 ng of cDNA. The standard thermal cycle settings for a reaction 
consisted in 40 cycles including a melt curve analysis (when using SYBR green). One cycle 
consisted of: 95ºC for 10 sec, 60ºC for 15 sec, 72ºC for 20 sec. TaqMan probes were bought 
from Thermo Fischer Scientific (Cambridge, UK) and corresponded to: IL-1 (Hs: 00174092), IL-
1 (Hs: 01555410_m1) IL-6 (Hs: 00985639), IL-8 (Hs: 00174103), B2M (Hs: 4325797).
Western blotting
Protein was extracted by dissolving the cell pellets on an appropriate volume of lysis 
buffer on ice. Lysis buffer which consisted in one tablet of complete mini-EDTA free protease 
inhibitor cocktail (Roche, Basel, Switzerland) and one tablet of phosphatase inhibitors 
(PhosSTOP, Roche, Basel, Switzerland) dissolved in 10 ml RIPA Buffer (Sigma-Aldrich, 
Gillingham, UK). Cell suspensions were left for 30 minutes on ice and centrifuged at 13.300 rpm 
for 10 minutes at 4 ºC. The supernatants were stored at -20 ºC and the pellets were discarded. 
Protein quantification was done using the bicinchoninic acid assay (BCA) (Thermo Fischer 
Scientific, Cambridge, UK) according to the manufacturer’s protocol using a TECAN 
spectrophotometer (Spark). 
Twenty micrograms of protein were mixed with 2x SDS lysis buffer, heated for 5 minutes 
at 95ºC and then loaded into 12% SDS-PAGE gels. Gels were run for  90 minutes at 150 V and 
transferred into nitrocellulose membranes using the Trans-Blot® Turbo™ Transfer System (Bio-
Rad, Deeside, UK) according to the manufacturer’s instructions. After transfer, membranes were 
blocked with 5% milk (Marvel) in TBS-T (Tris buffered saline 10mM, containing 0.5% Tween (v/v)) 
for 1 hour at room temperature in a rocking surface. The membranes were then incubated for 1 
hour at room temperature or overnight at 4°C on a rocking platform with the primary antibody at 
the working concentration in 5% TBS-T milk. After incubation, membranes where washed three 
times for 10 minutes intervals with TBS-T and incubated with the secondary antibody at working 
concentration in 5% TBS-T milk for 1 hour at room temperature in a rocking platform. The A
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membranes were then washed two times at intervals of 10 minutes with TBS-T and one time with 
TBS for 10 minutes and were ready for development. Membranes were developed with enhanced 
chemiluminescence (ECL), using Pierce ECL western blotting substrate (Thermo Fischer 
Scientific, Cambridge, UK), according to the manufacturer’s instructions. Signal was detected 
using a Li-Cor C-Digit Western Blot Scanner and Image Studio Software. 
Primary antibodies used were as follows: anti-p16 (1: 1000, 108349, Abcam, Cambridge, UK) 
and anti--actin (1: 10000, A1978, Sigma-Aldrich, Gillingham, UK).
Secondary antibodies used were as follows: anti-mouse IgG HRP-conjugated (1: 5000, 
GTX221667-01, Genetex, California, USA) and anti-rabbit IgG HRP-conjugated (1: 3000, 7074S, 
Cell signalling, London, UK).
Statistical analysis
Statistical analysis was done using Graphpad Prism 8 Software. Comparison of two 
groups was done using the un-paired t-test. When the comparison included more than two 
groups, one-way ANOVA (analysis of variance) was performed. A P-value < 0.05 was considered 
as statistically significant. The number of biological repeats is expressed as “N=” and the number 
of technical repeats as “n=”.
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FIGURE LEGENDS:
Figure 1: Y-27632 does not rescue oral keratinocytes from senescence
A, C: SA--Gal activity decreases after Y-27632 treatment in both NOK805 (A) and D6 (C) 
senescent cells but cells did not recapitulate cell growth. Scale bars are 50 m.
B, D: p16 expression in senescent NOK805 (B) and D6 cells (D) does not change after Y-27632. 
E: SA--Gal quantification in senescent NOK805 and D6 treated and non-treated cells. Data are 
shown as mean  SEM.
F: Population doublings of senescent NOK805 and D6 treated and non-treated cells. Data are 
shown as mean  SEM.
N = 3 independent experiments
Figure 2. Y-27632 modifies the SASP from senescent normal and dysplastic oral 
keratinocytes 
A-H: Effect of Y-27632 on secreted levels of IL-6, IL-8, IL-1 and IL-1 from senescent normal 
oral keratinocytes (A-D) and senescent dysplastic oral keratinocytes (E-H). Data are shown as 
mean  SEM (N = 3 independent experiments, n = 2 technical replicates). Two-tailed T-test was 
used to calculate the exact P value. 
Data information: *P < 0.05, **P < 0.005, P*** < 0.0005
Figure 3. Y-27632 modifies expression of IL-1 related genes which is not always reversible 
upon drug withdrawal A
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A-D: IL-1 (A), IL-8 (B), IL-1 (C) and IL-6 (D) gene expression during and after Y-27632 
treatment in normal oral keratinocytes. Data are shown as mean  SEM (N = 3 independent 
experiments, n = 3 technical replicates).One-way ANOVA with multiple comparisons was used to 
calculate the exact P value.
Data information: *P < 0.05, **P < 0.005, P*** < 0.0005, P**** < 0.0001
Figure 4. Oral keratinocytes immortalized with Y-27632 senesce after Y-27632 withdrawal
A-D:  Both NOK805 (A, B) and D6 (C, D) cells senesce after removal of Y-27632 from culture 
conditions, as shown by the increase in SA--Gal (A, C) activity and p16 expression (B, D). In the 
presence of Y-27632, NOK805 and D6 cells were still proliferative at passage 18 and 17 
respectively (A, C).  Scale bars are 50 m (N = 3 independent experiments).
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